Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 1Phosblock
02 1Renagel
03 6Renagel/Renvela
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 339
2018 Revenue in Millions : 448
Growth (%) : -24
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 288
2019 Revenue in Millions : 376
Growth (%) : -23
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sevelamer Hydrochloride and Sevelamer Carbonate
Main Therapeutic Indication : Urology
Currency : USD
2014 Revenue in Millions : -8.80%
2013 Revenue in Millions :
Growth (%) :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sevelamer Hydrochloride and Sevelamer Carbonate
Main Therapeutic Indication : Urology
Currency : USD
2015 Revenue in Millions : 752
2014 Revenue in Millions : 1,029
Growth (%) : 37%
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sevelamer Hydrochloride And Sevelamer Carbonate
Main Therapeutic Indication : Urology
Currency : USD
2016 Revenue in Millions : 977
2015 Revenue in Millions : 991
Growth (%) : -1
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sevelamer Hydrochloride and Sevelamer Carbonate
Main Therapeutic Indication : Urology
Currency : USD
2017 Revenue in Millions : 994
2016 Revenue in Millions : 1,143
Growth (%) : -13
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sevelamer Hydrochloride And Sevelamer Carbonate
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 464
2017 Revenue in Millions : 906
Growth (%) : -49%
LOOKING FOR A SUPPLIER?
